BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company Overview

Company: Bristol-Myers Squibb Company
CEO: Christopher S. Boerner
Founded: 1989
Symbol: BMY
Exchange: NYSE
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offeringslude Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Continue reading...

Bristol-Myers Squibb Company (BMY)

  • Stock Price
  • Volume
59.34 -8.54 -12.58%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Bristol-Myers Squibb Company annual revenue was $48.19 B in 2025.

Net Income

Bristol-Myers Squibb Company annual net income was $7.05 B in 2025.

Employees

Bristol-Myers Squibb Company annual employee count was 32,500 in 2025.

Revenue by Segment

Bristol-Myers Squibb Company’s revenue by segment: Abecma: $427.00 M, Abraxane: $368.00 M, Breyanzi: $1.36 B, Camzyos: $1.07 B, Cobenfy: $155.00 M, Eliquis: $14.44 B, Krazati: $205.00 M, Opdivo: $10.05 B, Opdivo Ovantig: $238.00 M, Opdualag: $1.19 B, Orencia: $3.71 B, Other Growth Brands: $1.92 B, Other Legacy Brands: $798.00 M, Pomalyst/Imnovid: $2.73 B, Reblozyl: $2.33 B, Revlimid: $2.95 B, Sotyktu: $291.00 M, Sprycel: $493.00 M, Yervoy: $2.90 B and Zeposia: $577.00 M in 2025.

Revenue by Region

Bristol-Myers Squibb Company’s revenue by region: Other Region: $1.09 B and UNITED STATES: $33.28 B in 2025.

Executive Salary

Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Office...

Revenue per Employee

Bristol-Myers Squibb Company revenue per employee was $1.48 M in 2025.

Profit per Employee

Bristol-Myers Squibb Company profit per employee was $217.02 K in 2025.

Income Statement

Operating Income

Bristol-Myers Squibb Company annual operating income was $12.70 B in 2025.

Research & Development

Bristol-Myers Squibb Company annual research & development expense was $9.61 B in 2025.

Tax Rate (%)

Bristol-Myers Squibb Company annual Tax Rate was 24.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Bristol-Myers Squibb Company annual total assets was $90.04 B in 2025.

Total Liabilities

Bristol-Myers Squibb Company annual total liabilities was $71.53 B in 2025.

Capital Expenditure

Bristol-Myers Squibb Company annual capital expenditures was -$1.31 B in 2025.

Ratios

Return on Equity (ROE)

Bristol-Myers Squibb Company annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Bristol-Myers Squibb Company annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Bristol-Myers Squibb Company annual debt to equity was 255.18% in 2025.

Profitability

Gross Profit Margin (%)

Bristol-Myers Squibb Company annual gross profit margin was 67.65% in 2025.

Operating Income Margin (%)

Bristol-Myers Squibb Company annual operating income margin was 26.34% in 2025.

Net Income Margin (%)

Bristol-Myers Squibb Company annual net income margin was 14.63% in 2025.

Earning Per Share

Bristol-Myers Squibb Company annual earning per share was $3.46 in 2025.

EBITDA

Bristol-Myers Squibb Company annual EBITDA was $14.55 B in 2025.

Free Cash Flow (FCF)

Bristol-Myers Squibb Company annual free cash flow(FCF) was $12.85 B in 2025.

Valuation

Enterprise value

Bristol-Myers Squibb Company annual enterprise value was - in 2025.

Enterprise value to Revenue

Bristol-Myers Squibb Company annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Bristol-Myers Squibb Company annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Bristol-Myers Squibb Company founded?

Bristol-Myers Squibb Company was founded on 1989, which makes the company 37 years old.

Sign up for free to view

Who is the CEO of Bristol-Myers Squibb Company?

Christopher S. Boerner is the CEO of Bristol-Myers Squibb Company.

What industry and sector is Bristol-Myers Squibb Company in?

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Bristol-Myers Squibb Company's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000014272
  • SIC (Standard Industrial Classification): 2834
  • ISIN (International Securities Identification Number): US1101221083

Sign up for free to view

How many employees does Bristol-Myers Squibb Company have?

Bristol-Myers Squibb Company has 32,500 employees.

What is the revenue of Bristol-Myers Squibb Company?

In fiscal year 2025, Bristol-Myers Squibb Company generated a revenue of $48.19 Billion.

What is the net income of Bristol-Myers Squibb Company?

In fiscal year 2025, Bristol-Myers Squibb Company reported a net income of $7.05 Billion.

What is Bristol-Myers Squibb Company's biggest product segment?

Eliquis is Bristol-Myers Squibb Company's biggest product segment, representing 29.97% of its total revenue.

When was Bristol-Myers Squibb Company listed on the stock exchange?

Bristol-Myers Squibb Company went public on Jun 1, 1972, through its Initial Public Offering (IPO), and it has been 54 years since then.

Sign up for free to view

What is the ticker symbol of Bristol-Myers Squibb Company, and where is it listed?

Bristol-Myers Squibb Company's ticker symbol is BMY, and the company is listed on the NYSE stock market exchange.

What is Bristol-Myers Squibb Company's current stock price?

Bristol-Myers Squibb Company's current stock price is $59.37 as of Jul 14, 2026.

What is Bristol-Myers Squibb Company's market capitalization?

As of , Bristol-Myers Squibb Company's market cap is .

What is Bristol-Myers Squibb Company's ranking in the world?

Ranked #18among 2,804 companies based on market cap.

Who are the top competitors of Bristol-Myers Squibb Company?

Competitors of Bristol-Myers Squibb Company include Eli Lilly and Company, Johnson & Johnson and AbbVie, and more.

People Also Search For

Submit feedback to Bullfincher